In a xenograft mouse model of multiple myeloma and BCL‐2, ABT‐263 exhibited increased toxicity when mice were treated with the BCL‐2, BCL‐XL, and BCL‐W inhibitor ABT‐263 (Tse et al., 2008). Here, BCL2L1 is linked to plasma cell myeloma.